|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
RedHill Biopharma Ltd. Appoints Key Opinion Leader Professor David Y. Graham from Baylor College of Medicine, Houston, Texas, as Lead Investigator for the US Pivotal Clinical Trial with RedHill's Crohn's Drug - RHB-104
10/10/2011 11:13:32 AM
TEL AVIV, Israel--(BUSINESS WIRE)--RedHill Biopharma Ltd. (TASE:RDHL), an emerging Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical-stage patented new formulations and combinations of existing drugs, announced the appointment of Professor David Y. Graham, MD, as the lead investigator of the Company's planned pivotal US clinical trial with RHB-104, its proprietary therapy for Crohn's disease. In this role, Prof. Graham will have broad responsibilities in the design of the clinical trial and will be actively involved in its execution and in the publication of its results.
|
|
|
|
|
|
|
|
|
|
|